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Sulnmitry 
CTL reactivity to the epitope MART-I{27_3s), of the melanoma (self) antigen MART-1/melan 
A is frequently observed in tumor-infiltrating lymphocytes and may be readily elicited from the 
peripheral blood of melanoma patients that express HLA-A*0201. Available data suggest that 
these observations contrast with those made for other HLA-A*0201-presented melanoma self 
antigens regarding the regularity of observed CTL responses. Based on preliminary findings, we 
hypothesized that the CTL response to MART-1  might be augmented in part by T  cell en- 
counters with peptides derived from sources other than MART-l, which show sequence simi- 
larity to  MART-1(27_3s). To test this  idea,  a  protein database  search for potential MART-1 
epitope mimics was done using criteria developed from analyses of effector recognition of sin- 
gly-substituted peptide analogues of MART-I(2v_3s ). Synthetic peptides were made for a por- 
tion of the sequences retrieved; 12/40 peptides tested were able to sensitize target cells for lysis 
by one or more anti-MART-1 effectors. The peptides recognized correspond to sequences oc- 
curring in a variety of proteins of viral, bacterial, and human (self) origin. One peptide derives 
from glycoprotein C  of the common pathogen HSV-1; cells infected with recombinant vac- 
cinia virus encoding native glycoprotein C  were lysed by anti-MART-t  effectors. Our results 
overall indicate that sequences conforming to the A2.1  binding motif and possessing  features 
essential  to recognition by anti-MART-1  CTL occur frequently in  proteins. These findings 
further suggest  that  T  cells  might  encounter a  variety of such  sequences  in  vivo,  and  that 
epitope mimicry may play a role in modulating the CTL response to MART-I(2v_3s). 
S 
everal melanoma-associated antigens have been identi- 
fied in recent years that are recognized by CD8 + CTL 
present  in  tumor-infiltrating lymphocytes (TIL)  ~ and  pe- 
ripheral blood of melanoma patients  (1).  Antigens recog- 
nized by these CTL fall into three main classes, comprised 
of mutated  cellular  proteins  (2-4),  ectopically  expressed 
proteins (5-7), and lineage-specific (non-mutated) self pro- 
teins  (8-13).  To  date,  CD8 +  T  cell  responses  to  HLA- 
A*0201-presented  epitopes  have  been  most  extensively 
studied, mainly due to the high prevalence of this class I al- 
lele  in  the  melanoma  patient  population  (14).  Among 
HLA-A*0201 + patients, CTL responses  directed to epitopes 
derived from the  melanocyte-specific self proteins  tyrosi- 
nase,  Pme117/gp100,  and  MART-1/melan  A  are  fre- 
quently observed. In particular, recognition of the MART- 
1Abbreviathms .sed in this paper: NP, nucleoprotein;  TIL, tumor-infiltrating 
lymphocytes. 
1(27_35  ) (AAGIGILTV) epitope is observed with high regu- 
larity  among  numerous  independently-derived TIL  lines 
(15,  16).  CTL  reactive  to  this  epitope  can  be  elicited 
readily from TIL and PBMC  of melanoma patients by in 
vitro stimulation  with MART-I(2v_3.~) peptide  (17,  18)  or 
with  HLA-A*0201 +  allogeneic  melanoma  cells  (19). 
Where comparisons have been made, responses to epitopes 
derived from tyrosinase or gpl00 were less frequently ob- 
served in TIL (15,  16),  or were less readily induced from 
peripheral blood ofHLA-A*0201  + patients  (18, 19). Though 
systematic,  comparative  studies  of responses  to  epitopes 
from tyrosinase, gpl00  and MART-1  are limited, a view 
emerges from these reports suggesting that the MART-1(27_as) 
epitope  may  be  "immunodominant"  among  melanoma/ 
melanocyte autoantigens (16). 
To gain a better understanding of the factors underlying 
the  CTL  response  to  MART-l{2v_35),  we  have  focused 
attention in this study on features intrinsic to the MART- 
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sponsiveness. We questioned whether a postulated mecha- 
nism  for  autoreactive T  cell induction,  involving epitope 
mimicry  (20-24),  might  play  a  role  in  the  self-directed 
CTL response to MART-1(27~3s  ). In particular, we sought to 
determine whether CTL in vivo might encounter mimics of 
the MART-l{27_.35) epitope derived from non-tumor sources, 
a circumstance which might result in an augmented popu- 
lation of CTL nominally specific for MART-1/27_3s). 
The central premise of epitope mimicry as an etiological 
mechanism is that T  cells triggered by a foreign (pathogen- 
derived)  antigen might in turn  react with a previously ig- 
nored  (25)  self antigen,  providing that  sufficient similarity 
exists  between  the  foreign  and  self epitopes  in  question 
(26).  This  premise  is  supported  by  accumulating  reports 
which suggest that TcR  specificities may not be as tightly 
restricted as previously imagined. Detailed studies of T  cell 
epitope  mimicry  have  thus  far  been  confined  mainly  to 
CD4 + T  cells and have indicated that synonymous epitopes 
may arise when  two  or more peptides simply share  select 
features important for TcR recognition (20-24). 
In  the  present  study,  variously derived MART-1{27_35/- 
specific effector populations were analyzed to define crite- 
ria  important  for  epitope  recognition,  and  to  effectively 
search for potential mimicry peptides. Our findings indicate 
that  MART-1<27_3s)-like  sequences,  potentially capable  of 
being endogenously presented by HLA-A*0201, occur with 
high  frequency  among  a  variety of self and  non-self pro- 
teins,  and  moreover,  that MART-1127_35/-specific effectors 
are capable of recognizing many such sequences. While we 
deem it unlikely that a  single mimetic agent underlies the 
anti-MART-1 CTL response in melanoma patients, one of 
the mimicry peptides we identified derives from the com- 
mon virus HSV-1, and is endogenously processed and pre- 
sented  by  HLA-A*0201-expressing  cells.  Our  combined 
observations suggest that CTL might encounter a variety of 
MART-1127_3s/-like sequences  in vivo, with various possi- 
ble functional consequences for the anti-tumor response to 
MART- 1  (27-35). 
Materials and Methods 
Peptides.  MAI<T-1(27_3s  /  derives  from  the  melanoma/mel- 
anocyte protein MART1/Melan A, and has the sequence AAG- 
IGILTV, in one-letter amino acid code. Flu Ml(5u_66  ), used as a 
control in these studies,  derives from the Influenza A matrix pro- 
tein M1  and has the sequence GILGFVFTL. The sequences and 
origins of other synthetic peptides are described in the text and 
figures.  All peptides were synthesized by standard F-moc, solid 
phase chemistry using a multiple peptide synthesizer (AMS Model 
422;  Gilson, Middleton, WI). Peptide quality after cleavage from 
the resin was assessed by HPLC and peptides generally were used 
without  further  purification.  The  purity  and  mass  of peptides 
shown  in  Fig.  3  were  further  analyzed by  mass  spectrometry. 
Peptide stock solutions were made at 1-5 mg/ml in pure DMSO. 
Cells.  Anti-MART-I  T  cell lines CLW and TIL-GDN are 
independently derived HLA-A*0201-restricted cytolytic effectors 
obtained from separate patients by either in vitro stimulation of 
patient  PBL  using  MART-1(27_3s) peptide-pulsed cells  (CLW) 
(17), or by high-dose IL-2, in vitro expansion of tumor-infiltrating 
lymphocytes (TIL-GDN) (15). Both T cell lines were determined 
to  be  >90%  CDS+/CD3 +.  Clone  A42  is  an  HLA-A*0201- 
restricted,  CD8 +  clone  which  specifically lyses  HLA-matched 
melanoma cell lines and MAP,  T-1{27_3s)-pulsed target cells,  and 
was initially isolated from TIL (10). Details regarding the genera- 
tion, characterization, and maintenance of these efector cells are 
described  in  the  sources  cited  above.  Anti-MART-1  clones 
620.41  and 620.62 were isolated by limiting dilution cloning of 
TIL 620  (15); clonality was verified by TcRV, sequence analysis 
as described previously (27).  An anti-influenza CTL line specific 
for  the  matrix peptide M1/5H_r /  was  generated  from  an  HLA- 
A*0201  individual by  in  vitro  stimulation  with  peptide-pulsed 
PBMC.  T2  cells  (28)  are HLA-A*0201 + human lymphoid cells 
that  are  defective in  antigen processing, but  effectively present 
exogenously supplied peptides.  LCL  72l  is  an  HLA-A*0201 +, 
Epstem-Barr virus  (EBV)-transformed  human  B  cell  line  (29). 
Both lymphoid cell lines were  maintained in ILPMI  1640  me- 
dium supplemented with 10% fetal calf serum. 
Vaccinia Constructs.  VV-gC5  (30),  kindly  provided  by  Dr. 
Barry Rouse (University of Tennessee), encodes native glycopro- 
tein C  of herpes simplex virus-I  (HSV-1), under the control of 
an early viral promoter. Vac-MART1 (31) and vac-NP (32), pro- 
vided by  Dr.  N.  Restifo  (Surgery Branch,  NCI),  are  vaccinia 
constructs that encode native MART-I protein and influenza nu- 
cleoprotein, respectively. 
Cytotoxicity Assays.  Standard 51Cr-release  assays were used to 
assess T  cell recognition of peptide-loaded target cells and  cells 
infected with recombinant vaccinia virus. In peptide loading ex- 
periments, StCr-labeled T2  cells were added to microtiter wells 
containing peptide and incubated at 37~  for 1 h before the addi- 
tion of CTL at the effector:target ratios indicated in the figures. 
For cold target inhibition experiments, unlabeled or 51Cr-labeled 
T2  cells  were  incubated  with  the  indicated peptides and  then 
washed extensively before use. CTL were added to microwells at 
a fixed effector/labeled target ratio; wells contained unlabeled and 
labeled T2 cells at the cold/hot target ratios shown. Experiments 
using vaccinia virus-infected target cells were done as previously 
described (31).  Briefly, LCL 721  cells  (10  ~' cells/nil) were incu- 
bated overnight at 37~  with 107 PFU/nfl of recombinant virus. 
After the incubation, cells were washed extensively and labeled 
with "S~Cr for use in lysis assays. 
TCRVt3 Analysis.  Quantitative assessment  of Vi3 gene  usage 
among CTL populations was carried out by PCR. To verify that 
the  PCP,-amplified product was proportional to  the amount  of 
the  target  template  in  the  original sample,  dilutions of T  cell 
cDNA  were  amplified by  PCR  with  TcRCr  primers 
(33). Amplification was done on a DNA thermal cycler (Perkin- 
Elmer Cetus) under the following conditions: 30 s denaturation at 
95~  30 s annealing at 60~  followed by a 1-min extension at 
72~  for 25  cycles.  Negative controls were  included with  no 
cDNA in the mixture. 10-1-1 aliquots of each PCR reaction were 
analyzed by Southern blot using a C~ oligonucleotide probe. Au- 
toradiographs were scanned using a Phosphorlmager (Molecular 
Dynamics,  Sunnyvale,  CA)  and  the  existing linearity between 
PCR-amplified products  and  cDNA  dilution  was  verified  for 
each sample. The same amount ofl3-specific cDNA template was 
then used for all of the samples in this study. 
PCR analysis of TcRVt3 usage was conducted using a panel of 
previously described oligonucleotide primers (34, 35), and carried 
out as described above except that 30 amplification cycles were 
used.  These  conditions allowed the  detection  of low levels of 
Tcl~V~  transcripts  and  prelinfinary  experilnents  showed  that 
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study accumulate exponentially. 
Results 
Recognition of MART-I(27.~s) Analogues.  To determine cri- 
teria  important  for  recognition  of the  MART-1  epitope, 
three HLA-A*0201-restricted, anti-MART-1  effector pop- 
ulations  were  assessed  for  their  ability  to  recognize  ana- 
logues of MART-l(27_3s  ) (Fig.  1).  A  total  of 46 analogues, 
singly-substituted  at  peptide  positions  P1-P9,  were  tested 
for their ability to sensitize T2 target cells for lysis by A42, 
CLW,  and  TIL-GDN  cells.  The  substitutions  employed 
were biased toward residues  having aliphatic/hydrophobic 
side  chains,  in  keeping  with  the  overall  character  of the 
parent peptide.  These peptides were tested at a concentra- 
tion  of 10  txg/ml  to  minimize  differences  in  recognition 
related to a given analogue's affinity for the A*0201  mole- 
cule. Effectors were tested at ratios of 20:1  and 5:1  (effec- 
tors/targets)  to obtain an indication of the efficiency of an- 
alogue recognition. 
Recognition by clone A42 was least tolerant of substitu- 
tions, especially at central positions (P3-P7) of the peptide. 
While  at  least  one  substitution  at  most  peptide  positions 
was permissive for recognition, none of the substitutions at 
P5 resulted in lysis ofpeptide-loaded T2 cells by A42 CTL. 
In contrast,  CLW and TIL-GDN effectors recognized the 
majority  of analogues  tested.  As  observed  for A42  CTL, 
recognition by CLW and TIL-GDN was most sensitive to 
substitutions  for  GIyP5  of MART-1(27_35/,  though  CLW, 
and  to  a  lesser  extent,  TIL-GDN,  were  both  capable  of 
recognizing  the  analogue  GlyP5  >Ala.  Additionally,  all 
three lines showed a similar preference for an aliphatic side 
chain  at  P6,  each  recognizing  the  isomeric  replacement 
IleP6 >Leu, as well as the analogue P6Val; P6Thr was also 
recognized  by  CLW  and  TIL-GDN.  While  residue  re- 
quirements  at  P3 were less  stringent  for CLW relative  to 
TIL-GDN  and  A42,  a  common  preference  is  observed 
among the three effector groups for a central  [G,A,V]xGx 
motif at P3-P6, where x is a residue with an aliphatic side 
chain (Leu, Ileu, or Val). 
One  implication  of these  results  is  that  GlyP5  plays  a 
crucial role  in  maintaining  the  epitope  recognized by the 
majority of anti-MART-l(27_3s)  TcR within these  effector 
populations.  Possibly, TcR contacts might be formed with 
peptide main chain atoms at this position, or the introduc- 
tion of a side chain at P5 might alter peptide conformation 
in a manner that disturbs TcR-peptide interaction at other 
positions.  Another  immediate  implication  of these  results 
concerns the TcR profiles of the CLW and TIL-GDN cell 
lines. While examination of Fig. 1 reveals specificity differ- 
ences  between  these  two  T  cell  populations,  the  overall 
similarity  of their  recognition  patterns  is  highly  apparent, 
suggesting  that  different  methods  of CTL  isolation  (see 
Materials  and  Methods  under  Cells)  have  given  rise  to 
functionally similar T  cell populations. To better character- 
ize these effector populations and to obtain a comparison to 
previously characterized anti-MART-1  CTL, TclkV~3 gene 
usage was analyzed in both CLW and TIL-GDN cell lines, 
as described below. 
To obtain  an indication  of whether the reactivities  ob- 
served for CLW and TIL-GDN might be typical for CTL 
lines, similar experiments were conducted using an anti Flu 
Mliss_66 ) CTL line  and singly-substituted  analogues  of the 
matrix  peptide.  Similar  results  (data  not shown)  were  ob- 
tained,  with respect to tolerance for conservative substitu- 
re 
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Figure 1.  Synthetic,  singly-sub- 
stituted analogs of the MART- 
1(27_35 )  peptide tested for  their 
ability to sensitize T2 cells for ly- 
sis by TIL-GDN, CLW and A42 
CTL.  Residue substitutions are 
shown at the bottom and top of 
the figure, along with residues of 
the  parent peptide  at  positions 
Pl-P9. The Flu M1(58.66 ) peptide 
is  used as a control. Solid and 
open bars indicate lysis obtained 
at  effector/target ratios of 20:1 
and  5:1, respectively. Results 
shown are representative of  those 
obtained in two or more experi- 
ments with each effector. 
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A  A  G  I  G  I  L  T  V 
MART 1  E  G  A  L  A  L  F  A  A 
Input pattern  F  I  V  p  T  I  E  L 
(1/102578)  I  L  V  V  V  F  T 
L  M  I 
V  P 
S 
G  I  L  G  F  V  F  T  L 
Ru M1  A  G  A  A  P  A  W  A  A 
input pattern  F  L  E  F  W  F  F  1 
(1/355693)  L  M  F  P  T  K  T 
T  V  I  T  P  V 
A  P  V  V 
T 
V 
Figure 2.  Input patterns used to initiate searches of the PIR protein da- 
tabase using the program.findpanerns. (Top) MART-1  pattern, showing 
residues allowed at each position in addition to those of the parent pep- 
tide, shown in bold. The general features of this pattern reflect the inclu- 
sion of residues permissive for HLA-A*201 binding (36) at anchor posi- 
tions P2 and P9, and the requirements imposed by T cell recognition for 
a limited variety of (mainly aliphatic) residues at positions P3-P7. Allowed 
residues  were  chosen based on  evaluation of ana]ogue  recognition 
datasets, and represent a compromise between  the stringency observed 
with clone A42 and the broader tolerance for substitutions observed with 
CTL  lines, as shown in Fig. 1.  The pattern combinatorially represents 
322,56{) different peptide sequences. (Bottom) Flu M1  pattern, obtained 
following analogue recognition assays  using a single anti-Flu effector line 
derived from a healthy donor. This pattern represents 864,000 different 
sequences. Shown with each pattern is the probability of finding 9-mer 
peptides meeting the specified requirements, calculated as described in the 
text. 
tions  at  most  positions,  indicating  that  CLW  and  TIL- 
GDN  are  not  unique  in  their  ability to  recognize  singly 
substituted analogues of their cognate peptide. 
Database  Search for  Potential  MAR T- I~eT_  ~s~  ,~/[imics. 
Guided by the analogue recognition results shown in Fig. 1, 
and by previously established residue preferences at anchor 
positions  P2  and  P9  of  HLA-A*0201-binding  peptides 
(36),  we  used  the  pattern  shown  in  Fig.  2  to  initiate  a 
search of the PlIk database using the programfindpaIterns  in 
the Genetics Computer Group software. This strategy was 
employed  previously  by  Wucherpfennig  and  Strominger 
(24)  to identify class II-presented epitope mimics. A  direct 
aligmnent search (37)  of the database was also done for the 
MA1KT-1(ev_3s ) sequence.  For the purpose  of comparison, 
data gathered from anti-Flu M1  effector recognition of ma- 
trix peptide analogues were  similarly used  to  compose an 
input pattern (also shown in Fig. 2) for thefindpattems  pro- 
gram. This search served as a control to determine the de- 
gree to which sequence similarities might be generally ob- 
served using a highly degenerate test sequence. 
The  findpatterns  search  for  "natural  analogues"  of 
MA1KT-I(2v_3s)  retrieved  348  non-identical  peptide  se- 
quences, while the search using the Flu M1  matrix peptide 
pattern retrieved only 69 non-identical sequences. This dis- 
parity in the number of sequences retrieved may be largely 
accounted  for  by  amino  acid  occurrence  rates.  Residues 
Gly,  Ala,  Val,  and  Leu,  featured  prominently  in  the 
MART1 
Flu M1 
Pseudorab|es  g.! 
HSV-2 gF" 
HSV-1 gC- 
Adenovlrus  3,7 E3 gp 
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E~ r  rant. synthsse 
B. polymyxa xylanase 
5treptornyces fineolnensls  ImrA 
S. cernvlslae ysa-1 
h glutamyltransferase 
h G protein-coupled  receptor 
h CD9 
a 
TIL- 
GDN 
CLW 
[] 
A42 
620.41 
[] 
620.62 
0  20  40  60  80  100  0  20  40  60  80  100  120 
% Specific SlCr Release (normalized) 
Figure 3.  Sensitization ofT2 cells for lysis  by anti-MAP,  T-1 CTL lines 
and clones by synthetic peptides derived from the proteins listed on the 
vertical axis. The sequences of the peptides shown appear in bold type in 
Table 1 Each peptide was tested at 10 btg/ml, using an effector/target ra- 
tio of 10:1 To permit clearer comparisons ofpeptide recognition by dif- 
ferent effectors, percent SICr release values are normalized to values ob- 
tained with MART-1 lay .~s~, set at 100%. 
MA1KT-1  pattern,  occur with  high relative frequencies in 
proteins.  Overall probabilities for  each  pattern,  calculated 
based on the percent occurrence of amino acids in a pooled 
database ofprokaryotic and mammalian proteins (38),  sug- 
gest that sequences conforming to the MART-1  input pat- 
tern are approximately three times more likely to occur at 
random than sequences specified by the Flu matrix peptide 
pattern, despite the difference in pattern degeneracy noted 
in  Fig.  2.  The  MA1KT-1  pattern  search  retrieved  120  se- 
quences  more  than predicted by chance  (n  =  228),  while 
the  number  retrieved  by  the  Flu  M1  pattern  search  was 
roughly equal to that suggested by probability alone (n =  66). 
CTL Recognition ofl  Naturally Occurrin~ Sequences.  Sequences 
retrieved  by  direct  alignment  were  examined  for  HLA- 
A*0201  binding motifs,  and  together with those  retrieved 
by findpauerns,  nearly  400  sequences  variously  similar  to 
MART-I{2v_3s  y were gathered for consideration. Inspection 
of these sequences led us to synthesize 40  candidate nmn- 
icry peptides.  Sequences  were  chosen  based primarily on 
how  closely  they  conformed  to  the  central  [G,A,V]xGx 
motif at P3-P6 ofMA1KT-I(e  7 3s), with preference given to 
sequences  derived from  pathogens  and  self proteins.  Test 
sequences  are  shown  in  Table  1.  These  peptides  were 
tested for their ability to sensitize T2  cells for lysis by A42, 
CLW,  and  TIL-GDN  cells,  and  by  two  additional  anti- 
MART  I  CTL  clones, 620.4l  and 62(I.62.  The results f~}r 
those peptides testing positive with at least one of the effec- 
tor groups are shown in Fig. 3; equivalent profiles were ob- 
tained using either 10 I.~g/ml (shown)  or 1 b~g/ml peptide. 
The sequences and proteins of origin of these peptides ap- 
pear in bold type in Table 1; the remainder tested negative 
in lysis assays. 
As depicted in Pig. 3,  CLW and TIL-GDN  cells recog- 
nized  7  and  9  of the  40  peptides,  respectively, in  nearly 
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Sequence  Species  Protein 
AAGIGILTV  Human 
AVGIGIAVV  Human 
IGGIGTVPV  Human 
LVVLGLLAV  Human 
ALGLGLLPV  Human 
AIV1GILIA  Human 
AVVIGIIIV  Human 
LGVIGLVAL  Human 
LLGLGVLET  Measles virus 
AMAPATIAA  Herpes simplex virus-1 
GIGIGVLAA  Herpes simplex virus-1 
GAGIGVAVL  Herpes simplex virus-2 
IAGIGILAI  Pseudorabies virus 
GAVPGIASV  Adenovirus 2 
LIVIGILIL  Adenovirus 3,7 
VDGIGILTI  Saccharomyces cerevisiae 
ALVIGIVTL  Saccharomyces cerevisiae 
IGAIGLIFT  Candida albicans 
LAGIGLIAA  Streptomyces lincolnensis 
LGGLGLFFA  Mycobacterium tuberculosis 
IAGPGTITL  Mycobacterium tuberculosis 
LAGVALLAT  Streptococcus gordonii 
EIVLGIIIA  Streptococcus mutans 
LIGLGLLSA  Bordetella pertussis 
IIVLGILIL  Pneumocystis carinii 
ALGLGVFAA  Pseudomonas putida 
FIGVALVAL  Pseudomonas aeruginosa 
LIAIAIFAL  Pseudomonas aeruginosa 
LIGLAVLST  Pseudomonas aeruginosa 
LVGIGVATA  Pseudomonas aeruginosa 
GAGIGVLTA  Bacillus polymyxa 
GVGLGVLSL  Yersinia enterocolitica 
LIALGVIIV  E. coli 
AGGIGIFTL  E. coli 
FMGIGLIAT  E. coli 
AAGIGIIQI  E. coli 
AIGIGILGG  E. coli 
QGGIGLLTV  E. coti 
PLGIGVLTT  E. coli 
LAVLGVLAL  E, coli 
QAGIGILLA  E. coli 
MART-1/melan  A  (27-35) 
CD9 
Glutamyl transferase 
G  protein-coupled receptor 
Glycoprotein C 
Glycoprotein F 
Glycoprotein III 
E3  9K glycoprotein 
ysa-1 
lmr A 
[~-endoxylanase 
Methionine synthase 
Hypothetical protein 
Synthetic peptides  screened for MART-1 (27-35)  mimicry and their origins. The peptides  shown represent  sequences  retrieved by both direct align- 
ment and pattern-based searches of the protein database; those marked by bold type sensitized T2 cells for lysis by at least one anti-MART-1 effector 
population. 
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1.  AV  O  Z  O  Z  AV  V  hCD9 
2.  L  V  V  Z,  o  x.  ~.  A  V  h  glutamyltranferase 
3.  A  ~.  e  '.  G  Z,  '.  P  V  h G  protein-coupled receptor 
4.  G  z  G  z  0  v  T.  A  A  HSV-1  gC 
5.  G  A  g  Z  ￿9  V  A  V  L  HSV-2gF 
6.  z  A  g  Z  g  Z  '.  A  I  Pseudorabies gill 
7.  L  Z  V  Z  Q  Z  Z,  T  L  Adenovirus 9Kglycoprotein 
8.  L  A  O  X  (]  T.  Z  A  A  Streptomyces  lincolnensis ImrA 
9.  V  D  O  "r  G  Z  r  T  I  Yeast ysa-1 
3.0.  G  A  O  Z  g  V  Y.  T  A  B. polyrnyxal~-endoxylanase 
11.  ~,  A  g  Z  e  Z  Z  Q  T  E.coli methionine synthase 
3.2.  Q  A  g  Z  G  Z  t,  5  A  E.coli hypothetical protein 
Figure 4.  Alignment of sequences recognized in lysis assays by one or 
more anti-MART-I  effectors. Residues at P3-P7 are shown in bold and 
yield the motif described in the text. 
identical fashion.  Few of the test peptides  were recognized 
by  clone  A42  (3/40  positive),  however  the  two  other 
clones  tested  recognized,  to  varying  degrees,  7  (clone 
620.41)  and  10  (clone  620.62)  of the  40 peptides.  Align- 
ment of the  12 sequences showing activity (Fig, 4) reveals a 
motif  at  P3-P7  comprised  by  [G,V]-[I,L]-[G]-[I,L,V]- 
[El,A];  bold letters  indicate  the  most frequent  residues  at 
each position. Comparison of active versus inactive peptide 
sequences  indicates  that conformity to this  P3-P7  motif is 
necessary  but  not  sufficient  for  recognition  by  anti- 
MAIKT-I(2v_3s ) effectors. The failure  of CTL to recognize 
some  test  peptides  bearing  this  motif could  reflect  poor 
peptide-class  I  binding,  or  residues  at  P1,2/P8,9  might 
force these peptides to adopt conformations that do not fa- 
vor productive TcR engagement. 
The test peptides recognized by anti-MART1  CTL de- 
rive from both self and non-self protein sequences. Among 
the species represented in Table  1, adenovirus and HSV-1 
are common and highly prevalent human pathogens.  The 
adenovirus  3/7-derived  peptide  was  recognized  only  by 
clone 620.62. The three viral glycoproteins from which syn- 
thetic  peptides  gl[l(4ss_463) (Pseudorabies  virus),  g0(480 488) 
(HSV-1),  and gF(446_454) (HSV-2)  are derived are members 
of the  herpesvirus  glycoprotein F  superfamily.  HSV-2 is a 
also common human pathogen, though not as prevalent as 
HSV-1.  Pseudorabies  virus  mainly  affects  swine,  and  gill 
has been described as an immunodominant antigen for cel- 
lular responses in swine and murine models (39). Likewise, 
CTL responses to gC have been noted in murine models 
of  HSV-1  infection  (40).  Of  the  HSV-derived  peptides, 
gF(44~_454) is recognized only by clone A42, while gC(480_488)- 
pulsed targets were lysed significantly by T  cell lines CLW 
and TIL-GDN, in addition to clone 620.41. 
The remainder  of the peptides  recognized in lysis assays 
derive from human, bacterial,  and yeast proteins.  The po- 
tential  significance  of these  other  reactivities  observed for 
anti-MAlkT-1  CTL  is  further  considered  below.  How- 
ever, given the prevalence of HSV-1 as a human pathogen 
and  the  observed  reactivity  of 3/5  effectors  to  the  gC- 
derived peptide,  we focused additional study on gCi480_488). 
A  dose-response  curve  for the  gC peptide  (Fig.  5),  using 
CLW  effectors,  indicates  that  significant  lysis  is  observed 
with  this  peptide  at  concentrations  of  100  ng/ml  and 
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Figure  5.  Dose-response plot of lysis obtained with T2 cells loaded 
with either MAIKT-l(27_:~s)  or gC(4sl  1488) at the concentrations indicated. 
CTL line CLW was used at an effector/target ratio of 10:1. 
above.  The MA1KT-1  peptide is at least  10-fold more po- 
tent  in  its  ability  to  sensitize  T2  cells  for lysis  by  CLW, 
however, judgments of relative potency are complicated by 
our observation that gC(48[)..488) is poorly soluble in aqueous 
media,  as  were  the  majority  of peptides  listed  in  Fig.  3, 
likely due to their high content of aliphatic residues. 
CTL  Recognition of Endogenously Processed HSV- I  gC. 
To  establish  whether  the  reactivity to  gC(48o_488) might be 
physiologically meaningful,  we  tested  the  ability  of CLW 
and  TIL-GDN to lyse  cells  expressing native  gC  protein. 
Using  vaccinia  constructs  separately  encoding  native 
MART-1  protein,  gC,  and influenza  nucleoprotein  (NP), 
M~ 
vac-MART  1 
vac-NP 
VV-gC5  [ 
I~  GDN 
￿9  CLW  ~//LIX//,////////~  II 
0  20  40  60  80  100 
%  Specific  SlCr Release 
Figure 6.  Lysis  of LCL 721 cells by anti-MART-1 CTL lines after in- 
fection of targets with recombinant vaccinia viruses encoding for either 
native MAP,,T-1 (vac-MART-I) or HSV-1 gC (VV-gC5). Lysis  obtained 
with vac-NP, encoding for the irrelevant antigen influenza nucleopro- 
tein, serves as a control for vaccinia infection. Also shown are results ob- 
tained using LCL 721 ceils pulsed with the indicated peptides at 1 }Xg/ml,  to 
compare presentation of endogenously processed versus exogenously  sup- 
plied antigen. 
652  T Cell Epitope  Mimics ofa Peptide Derived from Melanoma Antigen MART-1 100 
|  8o 
m  6o 
i  40  Cold target cells 
pre-pulsed with 
20  peptides: 
=  0  1:1  5:1  20:1  --  MART1 
----o---  gC 
B  A  FJu M1 
8 
40 F  2O 
0  1:1  5:1  20:1 
Cold:Hot target cell ratio 
Figure  7.  Inhibition  of lysis  mediated  by  TIL-GDN  using  peptide- 
pulsed  cold targets.  51Cr-labeled  T2 cells pulsed with  MART-i(27_35 ) (A) 
or gC{4s,}-4883 (B)  were mixed with unlabeled T2 cells pulsed with peptides 
as indicated in the key above. CTL were used at an effector/target  ratio of 
10:1. 
we observed that LCL 721 cells infected with vac-MART-1 
or VV-gC5 recombinants, but not vac-Flu NP, were lysed 
by both CLW and TIL-GDN effectors (Fig. 6). Thus, both 
MART-1  and  gC-derived  peptides  are  effectively pro- 
cessed  and  presented  through  the  endogenous  pathway. 
Under these assay conditions, equivalent levels oflysis were 
obtained for targets infected with vac-MART-1 or VV-gC5, 
despite the difference in peptide potency noted when using 
exogenously supplied peptides. 
Confirmation of Cross-reactivity.  Cold  target  inhibition 
experiments  were  done  to  confirm  that  recognition  of 
MART-l(27_35 ) and gC(480_488)  by T  cell lines is mediated by 
the same receptor(s). Unlabeled T2 cells pulsed with pep- 
tide  gC(480_488) effectively inhibited  lysis by TIL-GDN of 
SlCr-labeled target cells pulsed with MART-l(27_3s ) (Fig. 7). 
Similarly,  in  the  reciprocal  experiment,  MART-1(27_35  )- 
pulsed cold targets inhibited lysis of gC(480_488)-pulsed, la- 
beled T2 cells.  In addition, equivalent inhibition at differ- 
ent  cold/hot  target  ratios  was  obtained  in  each  case, 
whether  cold targets  were  pulsed  with  gC  or  MART-1 
peptide. Similar results  were obtained using CLW effectors 
(data not shown). These results indicate that the bulk of the 
lysis observed for target cells sensitized with either MART- 
1(27_38  ) or gC(480_488) peptide is mediated by the same TcR. 
Analysis of TcR Vr  Gene Usage.  The expression of  TcRV~ 
family  transcripts  in  effector lines  CLW  and  TIL-GDN 
(Fig. 8) showed both lines to be oligoclonal, suggesting an- 
tigen-driven selection. As a control, the TcRV~3 repertoire 
was  also  analyzed  in  fresh,  uncultured  PBL  of patient 
CLW. In peptide-stimulated effector line CLW, expression 
of many TcRV~ segments was absent or sharply decreased 
relative to  the uncultured PBL, while the relative expres- 
sion of Vf314 was significantly increased. As shown in Fig. 8, 
V~14,  V~4,  and  Vf33 in  peptide-stimulated  PBL together 
account for more  than  70%  of the  TcRV~  segments  ex- 
pressed. The increased representation of V~14 in the CLW 
effector line (21% versus 3% in fresh PBL) suggests that this 
TcRV~3, as well as V~4 and Vf33, could be directly involved 
in recognition of the MART-l(27_38) epitope. 
In TIL-GDN, V~I  and V~315 segments respectively ac- 
counted for 76 and  13% of the TcRV~ transcripts  (Fig.  8, 
bottom). Fresh GDN PBL were not available  for this study, 
precluding a comparative analysis and interpretation of this 
V~ expression pattern. However, the dominance of V~l and 
Vf315 transcripts  in  the  TIL-GDN population  is  strongly 
suggestive of a role for these V~ segments in recognition of 
the MART-l(27_38) epitope. 
The TcR of clone A42 previously has  been character- 
ized (27)  and uses V~7.  TcRVf3 sequence analysis of clone 
620.41  revealed that the TcR of this clone uses V~17;  data 
for clone 620.62 were not available  for this study. Detailed 
TcR analyses  of the  two  TIL 620-derived clones will be 
reported elsewhere. 
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Figure  8.  Autoradiogram  showing TcRVI3  expres- 
sion  in  fresh  PBL  from  patient  CLW  (top), anti- 
MART-1  CTL  line  CLW  (middle),  and  TIL-GDN 
(bottom).  Results were obtained following PCR ampli- 
fication of TcRV~ segments and Southern blotting, as 
described in Materials and Methods. TcRVIs segments 
are designated at the top of the upper panel. Following 
the nomenclature adopted by Wei et al.  (35),  VI~ seg- 
ments  17,  18,  19,  and  20  were  amplified by primers 
V1~-19, 17,  20,  and  18,  respectively. Numbers below 
lanes indicate the level of Vis expression as a percentage 
of the summed pixel values from all lanes after quanti- 
tation on a PhosphorImager; values are shown for ex- 
pression levels greater than 5%. The two MART-l-specific cell lines analyzed here dis- 
play different TcRVI~ repertoires characterized by the pre- 
dominant expression  of two to three V~ transcripts.  Prior 
analyses  have  revealed  common  usage  of V~14  and  V~7 
segments  among  TIL-  and  PBL-derived  anti-MART-1 
clones from different melanoma patients (reviewed in ref- 
erence 41),  and anti-MART-1  clones using V~3  (27)  and 
V~4 (42) have also been described. These previous analyses 
have  also  revealed  that  anti-MART-1  TcR,  from  mela- 
noma patients are generally characterized by restricted Vf3 
usage and  CDR3  regions  of diverse length  and  composi- 
tion  (41).  Overall,  the  CTL  lines  studied  here  appear  to 
embody characteristics typical of MART-l-reactive effec- 
tors described to date. 
Discussion 
While  numerous  factors  affect immune  responsiveness, 
especially to self antigens,  we sought in the present study 
to  investigate  whether  sequences  closely  related  to  the 
MAR_T-l(27_35  ) epitope, AAGIGILTV, derived from sources 
other  than  MART-l,  might  be  encountered  by the  im- 
mune  system  and  potentially  play  a  role  in  shaping  the 
anti-MART-1  CTL response. The criteria for "similarity" 
to  MART-l~27_.~5) derive  from  requirements  imposed  by 
both T  cell  recognition  and binding  to the  HLA-A*0201 
molecule. These requirements lead to a consensus sequence 
dominated by aliphatic  residues,  a  feature  contributing  to 
the retrieval of a large number of sequences, variously sim- 
ilar to MART-l(27_3s  ) , from the protein database. 
Alignment of the  12  naturally occurring sequences rec- 
ognized by anti-MART-1  effectors in this study indicates 
close  conformity to  the  MART-1(27_3s ) parent  peptide  at 
P3-P7;  all  of these  mimics  contain  Gly  at  P5.  Previous 
studies  of class  lI-presented  mimicry  peptides  have  indi- 
cated a similar requirement for maintenance of identity or 
close similarity to the parent peptide at two to three critical 
residues  (20,  21,  24),  though some of these mimics lacked 
extensive identity or similarity to the parent peptide over- 
all. Class  I  and  class II molecules are  distinguished  by the 
closed (class I) versus open (class II) design of their respec- 
tive peptide  binding  grooves  (43,  44).  Peptides  bound  to 
HLA-A2  and  related  allomorphs  are  anchored  at  their 
anfino and carboxy temfini, while side chains in the pep- 
tide  mid-region  tend  to  adopt  sequence-specific  orienta- 
tions  (43).  This  feature  may  impose  constraints  on  the 
range of sequence possibilities available to class I-presented 
nfimics. In general, however, our results are consistent with 
the suggestion arising from class II studies that overall, sig- 
nificant sequence identity does not guarantee, nor is it a re- 
quirement for, TcR recognition. 
Given the currently limited representation of proteins in 
the  database,  the  number  of MART-I(2  v 3s)  mimics  may 
not be limited to  the sequences described here.  The rele- 
vance of our observations is predicated on at least a subset 
of these  mimicry peptides  being  endogenously  processed 
and  presented  by cell  surface  HLA-A*0201  molecules.  If 
so,  then  circulating  CTL  could  encounter  au  array  of 
epitopes similar to MART-t(27_3s)  contributed from a vari- 
ety of self and non-self proteins. 
The HSV-l-derived peptide gC(481)_488)  fulfills  the mini- 
real  criteria  for  a  pathogen-derived  epitope  mimic  that 
could  play  a  role  in  potentiating  the  anti-MART-1  re- 
sponse.  Our  data  indicate  HLA-A*0201-expressing  cells 
endogenously  process  and  present  a  gC-derived  epitope 
recognized  by  a  subset  of anti-MA1KT-l(27_3s ) CTL,  and 
that these  effectors recognize  gC(480_488) in  a  cross-reactive 
fashion.  HSV-1  (non-genital herpes)  infection is common 
among humans, and a majority of adults show evidence of 
prior exposure to this virus (45).  CTL responses to HSV-I 
in  humans  remain  poorly  characterized  (46),  and  to  our 
knowledge,  HLA-A*0201-restricted  CTL  epitopes  have 
not been described. While it is unlikely that HSV-1  plays a 
primary causative role in the anti-MART-1  response, it is 
plausible that exposure to HSV-1, or to multiple pathogens 
contributing similar epitopes, could result in the generation 
of CTL which are subsequently recruited in the response to 
tumor-derived MART-I(2v_3s)  in HLA-A*0201  melanoma 
patients. It will be of interest to determine whether anti-gC 
CTL  can  be  raised  from  melanoma  patients  or  donors 
which subsequently cross-react with MART-l(27_35). 
Our combined observations raise  alternative possibilities 
for mimicry playing a role in shaping the anti-MART-l(ev_35 ) 
CTL response. The anti-MART-1  effectors we tested also 
recognized peptides derived from hmnan (self)  and Escheri- 
chia coli (commensal self) proteins. Thymic presentation of 
a variety of MART-l-like self sequences might play an im- 
portant role in positive selection of T  cells,  shaping a TcR 
repertoire  that  is,  to  a  degree,  biased  toward  recognizing 
such sequences  (47,  48).  There is also  evidence indicating 
that bacterially derived antigens can elicit CD8 + responses 
(49,  50),  and that E.  coli sequences in particular are visible 
to  the  immune  system (51).  The  consequences  of poten- 
tially constitutive, peripheral presentation of mimicry pep- 
tides  are  difficult  to  predict;  these  epitopes  might  be  ig- 
nored  entirely,  or perhaps may drive low level expansion 
and/or anergy (52)  of reactive CTL and contribute to tol- 
erance in vivo. 
A puzzling aspect of the anti-melanoma, anti-MART-I 
CTL  response  is  the  apparent  inability  of these  CTL,  in 
many cases, to effectively eradicate tumors in vivo. A num- 
ber  of mechanisms  may contribute  to  tumor  escape,  in- 
cluding downregnlation of MHC and/or antigen (53), pos- 
sibly  as  a  result  of immunoselection  (54).  In  this  case, 
MART-l-like  sequences  in  the  periphery  might  act  to 
maintain  an  expanded  population  of anti-MA1KT-I  CTL 
whose anti-tumor function is obsolete. 
However, it appears that anti-MART-1 CTL in vivo of- 
ten do not elaborate a full-blown autoimmune response. A 
recent study examined the effect of imnmnizing melanoma 
patients  with  MART  1(27_35  )  peptide  (Cormier, J.,  M.L. 
Salgaller,  T. Prevette, L. Rivoltini, K.C. Barracchini, N.P. 
Restifo, S.A. Rosenberg, and F.M.  Marincola, manuscript 
submitted for publication).  Immunization significantly in- 
creased anti-MART-l(2v_3s) CTL reactivity recovered from 
peripheral blood, though clinical improvement was not ap- 
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role for MART-l-like  sequences  in shaping CTL  activity 
in vivo. In the context of an anti-MART-1 response to tu- 
mor,  T  cell encounters  with  MART-1{27_35)-like peptides 
acting as partial agonists or antagonists (55, 56) might result 
in negative modulation of the CTL response. 
We view the utility of the analysis described here as two- 
fold.  A  comprehensive  search  for  mimicry peptides  can 
potentially  uncover  undesirable  reactivities  to  other  self 
peptides, a matter of general importance to self epitope-tar- 
geted  immunotherapy.  In  addition,  this  type  of analysis 
may provide a  starting point for asking new  questions  re- 
lated to how CTL responses might be shaped in vivo. 
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